The Alliance for Regenerative Medicine (ARM) outlines in their regular snapshots that the gene therapy landscape addresses more prevalent or systemic indications.  This switch suggests that a large part of these therapies will need to be manufactured at the highest scale to deliver large quantities of vectors per year.  To address the growing demand for industrial-scale adeno-associated virus (AAV) production, Cytiva has recently launched an innovative stable, helper virus-free AAV production platform called ELEVECTA™ HEK producer line. In this work, we have modeled different scenarios of process optimization based on the ELEVECTA stable platform and compared them with our transient cell line process. We have analyzed how they compare in terms of the cost of manufacturing per year.